Page 52 - Read Online
P. 52
Genvigir et al. J Transl Genet Genom 2020;4:320-55 I http://dx.doi.org/10.20517/jtgg.2020.37 Page 337
Ref. [49] [65] [13] [14] [59] [37] [29] [27] [38]
Clinical outcomes No association of SLCO1B1 c.388A>G and 463C>A variants with neutrophil counts No association of SLCO1B3 c.334T>G (or 699G>A) variant with diarrhea No association of SLCO1B3 c.334T>G variant with AR or adverse events - No association of SLCO1B3 c.334T>G (or 699G>A) variant with - No association of SLCO1B3 c.334T>G variant with AR or adverse events No association of SLCO1B3 c.334T>G and rs1104585 variant
Pharmacokinetics No association of SLCO1B1 c.388A>G and 463C>A variants with MPA exposure (AUC) SLCO1B3 c.334GG (699AA) genotype was associated with higher exposure to MPA (AUC 6-12) - SLCO1B3 c.334GG genotype was associated with lower MPA peak concentration and exposure (AUC 0-12 ) and higher MPAG/MPA ratio, on cyclosporine-free treatment (n = 70) No association of SLCO1B3 c.334T>G (or 699G>A) variant with exposure to MPA, MP
Immunosuppressive regimen MMF Tacrolimus Corticosteroid-free One-year follow-up MMF Tacrolimus Corticosteroids At day 28 MMF Cyclosporine Tacrolimus mTOR inhibitor Corticosteroids One-year follow-up MMF Cyclosporine Tacrolimus Sirolimus Corticosteroids At a point between 3-6 months MMF Cyclosporine Tacrolimus Corticosteroids One-year follow-up MMF Cyclosporine Corticosteroids EC-MPS Cyclosporine Corticosteroids Six-month
Population 21 adult patients (Canada) 87 adult patients (Japan) (France) 185 patients (France) 338 adult patients 37 adult patients (China) 189 adult patients (France) 284 pediatric and young adult patients (USA) 408 adult patients (China)
Study design Prospective Prospective Retrospective (Transgene 218 adult patients study) Prospective (included multicenter Apomygre study) Prospective (FDCC Study) Prospective, Multicenter (Case-control) Prospective, multicenter (Dominos study) Retrospective (Case- Control), multicenter Retrospective
Allele frequency c.388G: 48% 463A: 10% c.334T: 34% 699G: 34% c.334T: 17% c.334T: 18% 767C: 15% c.334T: 19% c.334T: 30% c.334T: 15% - c.334T: 29%
rs4149117 (c.334T>G) rs7311358 (c.699G>A) rs1104585 rs60140950 (c.767G>C)
Variant
Gene SLCO1B3